Thermo Fisher Scientific Inc. TMO

Demand for biologics, targeted therapies and personalized medicine is rising, while AI-led protein design and scalable bioprocessing unlock new opportunities.Dublin, Sept. 30, 2026 (GLOBE NEWSWIRE) -- "Recombinant Proteins Market - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global recombinant proteins market was valued at US$3.3 billion in 2024 and is projected to reach US$5.8 billion by 2030, expanding at a compound annual growth rate of 10.2%. Ma

Fetal Bovine Serum Market Gains Momentum as Stem Cell Research, Vaccine Innovation and Advanced Therapies Drive Demand for High-Quality, Ethically Sourced ProductsDublin, Sept. 30, 2026 (GLOBE NEWSWIRE) -- "Fetal Bovine Serum Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035" has been added to ResearchAndMarkets.com's offering. The global fetal bovine serum market was valued at USD 1.1 billion in 2025 and is projected to reach USD 2.3 billion by 2035, expanding

Thermo Fisher Scientific has been a strong performer over the past year, and that kind of run naturally raises a pointed question for anyone looking at the stock today. Is the current share price aligned with the cash flows the business is expected to generate, or has sentiment moved ahead of the underlying economics? The stock has returned 47.4% over the past year, which puts real pressure on the question of whether the current valuation still lines up with the cash being produced and...

On September 23, Thermo Fisher Scientific Inc. (NYSE:TMO) announced the launch of the Gibco CHO-K1 Catalog Panel, a cGMP-ready portfolio of basal and feed media designed to accelerate cell growth and protein production for CHO-K1 host lines used in biologics and biosimilars development. Offered in liquid and dry powder formats, the ready-to-use catalog panel enables […]

Earlier this month, Thermo Fisher Scientific announced several product and collaboration updates, including the cGMP-ready Gibco CHO-K1 Catalog Panel for bioprocessing, a reseller agreement to distribute Evosep’s Eno separation platform in proteomics workflows, and expanded involvement in molecular residual disease programs with Biodesix and Memorial Sloan Kettering. Together, these moves deepen Thermo Fisher’s role across biologics manufacturing, advanced proteomics, and ctDNA-based cancer...

Gilead Sciences, Inc. (NASDAQ:GILD) and Thermo Fisher Scientific Inc. (NYSE:TMO) are benefiting from two very different sources of growth. Gilead’s momentum is being driven primarily by its HIV portfolio, where established medicines and newer products are expanding rapidly. Thermo Fisher, meanwhile, is beginning to benefit from strengthening customer activity across the life-sciences markets it serves […]

WALTHAM, Mass., September 28, 2026--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the third quarter 2026 before the market opens on Wednesday, October 21, 2026, and will hold a conference call on the same day at 7:00 a.m. ET. During the call, the company will discuss its financial performance, as well as future expectations.

Boost ROI through standardized QC, auditable automation, validated AI, diversified reagent sourcing, regional partnerships, and cross-skilled workforce trainingDublin, Sept. 28, 2026 (GLOBE NEWSWIRE) -- "Cell Line Generation Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. This market research report examines the global cell line generation market, which is projected to reach USD 1.42 billion in 2026 and grow at a CAGR of 10.86% to USD 2.67 billion by 2032

Demand is rising in diagnostics, precision medicine and biopharma research, while nanotechnology, automation and AI unlock targeted therapies and high-throughput workflows.Dublin, Sept. 28, 2026 (GLOBE NEWSWIRE) -- "Magnetic Beads - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global magnetic beads market was valued at an estimated US$3.3 billion in 2025 and is projected to reach US$7.4 billion by 2032, advancing at a compound annual growth rate (CAG

Boost ROI via automated closed handling, resilient sourcing, tailored portfolios, quality-by-design, validated AI, compliance mapping and lifecycle stewardship.Dublin, Sept. 28, 2026 (GLOBE NEWSWIRE) -- "Grignard Reagents Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. The Grignard Reagents Market research report provides a comprehensive assessment of industry growth, production trends, applications, technologies, and geographic opportunities. The market

Thermo Fisher Scientific to offer the Evosep Eno separation platform to customers, expanding access to standardized, high-throughput proteomics workflowsSINGAPORE, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Evosep™, a global leader in standardized proteomics solutions, today announced a reseller agreement with Thermo Fisher Scientific, the world leader in serving science. Through this agreement, Thermo Fisher Scientific will offer the Evosep Eno™ separation platform as part of its portfolio of mass spec

Pfizer Inc. (NYSE:PFE) and Thermo Fisher Scientific Inc. (NYSE:TMO) are both trying to put difficult post-pandemic periods behind them, but their recoveries look very different. Thermo Fisher is benefiting from improving activity across life-sciences markets after a prolonged slowdown in pharmaceutical and biotech spending. Pfizer, meanwhile, is trying to rebuild growth around newer medicines as […]

A $10,000 holding in Twist Bioscience (TWST) a year ago is worth about $66,600 today. The same sum in the S&P 500 would be worth about $11,700. The company sells made-to-order DNA to drug makers and research labs. Its sales grow fast, but it still loses money. The price now counts on that growth lasting and the losses ending. How much has to go right for that price to hold.

Dodge & Cox Fund, an investment management company, released its second-quarter 2026 investor letter for “Dodge and Cox Stock Fund”. You can download a copy of the letter here. U.S. equities achieved new all-time highs in Q2 2026, driven by a rally in the technology sector, led by memory semiconductor stocks. In Q2 2026, the […]

Opportunities include automated closed systems, AI-enabled quality control, single-cell and cell therapy workflows, precision medicine, advanced diagnostics and emerging-market expansion.Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- "Cell Isolation/Cell Separation Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. The market research report examines the global Cell Isolation/Cell Separation Market, which is projected to reach USD 6.97 billion in 2026 and grow a

Opportunities center on automated, standardized TDM kits integrated with AI dosing tools for antimicrobial stewardship, transplant care and precision medicine, especially in Asia-Pacific.Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- "TDM Reagent Kit Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. This market research report examines the global TDM Reagent Kit Market, projected to reach USD 2.87 billion in 2026 and grow at a CAGR of 15.84% to USD 6.96 billion

Biodesix, Inc. (NASDAQ:BDSX) reported progress in two collaborative Molecular Residual Disease (MRD) monitoring programs designed to detect circulating tumor DNA (ctDNA) in blood following cancer treatment.